 Enzo Biochem, Inc. ENZ, a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624,863 entitled Sphingosine Kinase Type 1 Inhibitors and Uses Thereof. The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the companys proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors. In February, Enzo reported the publication of work by academic researchers demonstrating that drug candidate SK1-I decreased Interferon IFN signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney, in a chemically induced mouse model of lupus. 